The world's most efficient pharmaceutical companies TOP list released! There are only 3 pharmaceutical companies in the century, AbbVie, Pfizer, Lilly...

How can a pharmaceutical company stay efficient?

Large pharmaceutical companies usually have strong capital and strong talent teams, and can improve the overall winning rate
through mergers and acquisitions, product pipelines and other means.
And biotech companies usually have an advantage in a certain frontier field, and what they have to do is focus on their own track and technology, and then wait for the wind to come
.

Recently, the industry media Fierce Pharma released the world's most efficient biopharmaceutical companies in 2021 TOP10, confirming this
.

Overall, 9 of the 10 companies on the list are generating more than $1 million in revenue per capita, up from just four five years ago
.
Seven of these 10 companies have benefited from COVID-19 vaccines or COVID-19 drugs and have significantly increased per capita revenue generation
.

Note: The list only counts pharmaceutical companies with revenues of more than $10 billion in 2021; Revenue per capita is revenue for 2021 divided by the total number of employees in the company Data source: References

With mRNA COVID-19 vaccine

BioNTech/Moderna topped the list

Three years ago, with the COVID-19 pandemic and the success of the mRNA COVID-19 vaccine, BioNTech and Moderna topped the list of the world's most efficient pharmaceutical companies
.
The two companies, each with about 3,000 employees, generate about $20 billion in revenue and generate nearly $7 million per capita, far higher than Gilead Scientific, which ranks third
.

But in terms of R&D models, BioNTech and Moderna take a different approach
.

BioNTech has chosen to partner with pharmaceutical companies such as Pfizer and Fosun Pharma in China to bring its COVID-19 vaccine to market
quickly.
But that hasn't diminished the strength and earnings
of the German biotech company.

By the end of 2021, BioNTech had 3,082 employees worldwide, approximately 1,000 more than in 2020, generating $7.
28 million per capita in 2021, making it the most efficient biopharmaceutical company in the
world.

This year, BioNTech is also continuing to add staff, expand manufacturing, and develop mRNA production programs
.
Its plant in Marlborough, Germany, is already one of the world's largest mRNA vaccine factories, but BioNTech said it will also invest about 50 million euros (about $56.
4 million
).
In addition, BioNTech's collaboration with companies such as Regeneron in the field of cancer has set its sights on future mRNA projects and other projects
such as cell therapy.

Unlike BioNTech, Moderna does not take the initiative to cooperate, but plans to build its own mRNA empire
.

To achieve this, Moderna's workforce grew rapidly from 820 in 2019 to 2,700 in 2021
.
With its mRNA COVID-19 vaccine Spikevax, Moderna achieves revenue of $18.
47 billion in 2021 and $6.
84 million per capita, just below BioNTech
.

In February, Moderna said it would expand its sales territory
by opening four new subsidiaries in Hong Kong, Malaysia, Singapore and Taiwan.
Moderna also plans to develop commercial projects
in Europe such as Belgium, Denmark, the Netherlands, Norway, Poland and Sweden.
Next, Moderna will continue to develop mRNA therapies
against diseases such as flu and cancer.

With 14,400 employees, Gilead generated $27 billion in revenue in 2021 and generated approximately $1.
95 million
per capita.
Of course, Gilead also made $5.
6 billion in sales
from the coronavirus drug Veklury.

Ranked fourth in the regenerative unit, it already has one
of the most efficient workforces in the biopharmaceutical sector until 2021.
In the past, the company has developed blockbuster drugs such as Eylea, a blockbuster drug for macular degeneration, and Dupixent, which treats eczema and asthma
.

When the coronavirus erupted, regenerative reacted quickly by launching the COVID-19 antibody cocktail therapy "REGEN-COV" to treat high-risk populations
.
The therapier will have revenues of $7.
574 billion in 2021, helping regeneration elements make the list
.

M&A & Alliances

Big pharmaceutical companies use their strength to break through

Pfizer has partnered with BioNTech to obtain the right to co-develop its mRNA vaccine (trade name: Comirnaty) in the United States and Europe, achieving nearly $37 billion in sales through the vaccine in 2021 and nearly doubling
Pfizer's per capita income in 2021 compared to 2020.
Pfizer, on the other hand, spun off its generic division Upjohn in the fourth quarter of 2020, controlling the number of employees and generating $1.
03 million
in revenue per capita.

Sales of Olumiant, a collaboration between Eli Lilly and Incyte for patients with severe COVID-19 and companies such as Junshi Biologics, reached $2.
24 billion, or about 8%
of total sales.
In fact, Lilly has been cutting costs and ramping up new drug research and development efforts to improve the company's efficiency
for many years.
In early 2017, shortly after CEO David Ricks took the helm, the company launched a massive cost-cutting campaign aimed at saving $1.
2 billion a year.

At the same time, Eli Lilly's revenue grew during this time, significantly increasing productivity
per employee.
Since the beginning of this year, Lilly has come up with a number of blockbuster pipeline advances that shake the industry, including Tirzepatide receiving FDA approval, Empagliflozin adding indications for heart failure and ending early in the Phase III clinical endpoint of CKD, Baricitinib's new alopecia areata indications, and Mirikizumab's submission of BLA
.

In addition, Celgene and Allergan, which were on the list in 2016, have been acquired by Bristol-Myers Squibb (BMS) and AbbVie respectively, which have allowed these two companies to occupy a place
in the TOP list of the world's most efficient pharmaceutical companies in the past two years.

In 2019, BMS acquired Xinji
, which ranked second that year, for $74 billion.
After the merger, BMS saved costs through integration, layoffs and other means, and due to the growth in sales of best-selling drugs such as Revlimid, Eliquis and Opdivo, BMS ranked fifth in this year's list, the highest ranking among established pharmaceutical companies with more than a
century-old history.

Also in 2019, AbbVie acquired Airgan and generated $4.
68 billion in revenue last year, up 87%
from 2020.
But AbbVie's immunological blockbuster – Humira – remains the company's main source of revenue, with sales of $20.
7 billion in 2021, accounting for 37%
of AbbVie's total sales.
With Humira set to face tremendous generic pressures in 2023, it remains to be seen
how AbbVie's future financial position will be maintained.
However, revenue growth from its new immunology products, Skyrizi and Rinvoq, is impressive, and AbbVie expects total sales of these two immune drugs to reach $15 billion
by 2025.

Compared to the rapid progress of other biopharmaceutical companies, Amgen has been slightly unfazed
in recent years.
Like BMS and AbbVie, Amgen has not been successful in launching COVID-19 products in the past few years, but Amgen will reach $25.
98 billion in global sales and $1.
07 million in revenue per capita in 2021, surpassing most companies
in the industry.
In addition, last year, Amgen's new lung cancer drug Lumakras, which was approved by the FDA for listing, has attracted much attention, and after breaking the curse of KRAS infallibility, a number of combined drug data were released at WCLC this year, which is expected to become a blockbuster drug
.

Of course, new drug development isn't always so lucky
.
In 2021, due to multiple factors such as the failure of the Alzheimer's drug Aduhelm and the market preemption of generic drugs for multiple sclerosis, Bojian generated lower per capita revenue in 2021 than in 2020, and is the only company in the list whose
average income is reduced.

Original English: